title: Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
abstract: A Phase I trial (NCT00109109) of oral vorinostat 200, 250 or 300 mg twice daily for 5 days/week/4-week cycle or 200, 300, or 400 mg twice daily for 14 days/3-week cycle until progressive disease or intolerable toxicity was conducted. Patients with measurable, relapsed/refractory multiple myeloma were eligible. The objectives were to determine maximum tolerated doses (MTDs) and assess activity and safety. Thirteen patients (median age, 63 years; median prior therapies, 3) were enrolled. MTDs were not determined due to early study termination by sponsor decision. One patient (250 mg twice daily 5 days/week) developed dose-limiting toxicity (DLT; grade 3 fatigue). There were no other DLTs and the maximum administered doses were 250 mg twice daily for 5 days/week/4-week cycle and 200 mg twice daily for 14 days/3-week cycle. Drug-related adverse experiences included fatigue, anorexia, dehydration, diarrhea, and nausea and were mostly grade <or=2. Of 10 evaluable patients, 1 had a minimal response and 9 had stable disease, demonstrating modest single-agent activity in relapsed/refractory multiple myeloma.
authors.affiliation: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Richardson
authors.forename: Constantine
authors.initials: C
authors.lastname: Mitsiades
authors.forename: Kathleen
authors.initials: K
authors.lastname: Colson
authors.forename: Eileen
authors.initials: E
authors.lastname: Reilly
authors.forename: Laura
authors.initials: L
authors.lastname: McBride
authors.forename: Judy
authors.initials: J
authors.lastname: Chiao
authors.forename: Linda
authors.initials: L
authors.lastname: Sun
authors.forename: Justin
authors.initials: J
authors.lastname: Ricker
authors.forename: Syed
authors.initials: S
authors.lastname: Rizvi
authors.forename: Carol
authors.initials: C
authors.lastname: Oerth
authors.forename: Barbara
authors.initials: B
authors.lastname: Atkins
authors.forename: Ivy
authors.initials: I
authors.lastname: Fearen
authors.forename: Kenneth
authors.initials: K
authors.lastname: Anderson
authors.forename: David
authors.initials: D
authors.lastname: Siegel
mesh_terms: D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage* / Q000633:toxicity; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D016879:Salvage Therapy / Q000379:methods; D016896:Treatment Outcome; D000077337:Vorinostat
chemical_list: D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat